Identification of Homeodomain Proteins, PBX1 and PREP1, Involved in the Transcription of Murine Leukemia Virus

REFERENCES

• Berthelsen, J., C. Kilstrup-Nielsen, F. Blasi, F. Mavilio, and V. Zappavigna. 1999. The subcellular localization of PBX1 and EXD proteins depends on nuclear import and export signals and is modulated by association with PREP1 and HTH. Genes Dev. 13: 946–953.
   PubMed Web of Science ®Google Scholar
• Berthelsen, J., V. Zappavigna, E. Ferretti, F. Mavilio, and F. Blasi. 1998. The novel homeoprotein PREP1 modulates Pbx-Hox protein cooperativity. EMBO J. 17: 1434–1445.
   PubMedGoogle Scholar
• Bustin, M., and R. Reeves. 1996. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol. 54: 35–100.
   Google Scholar
• Carlson, B. A., M. M. Dubay, E. A. Sausville, L. Brizuela, and P. J. Worland. 1996. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56: 2973–2978.
   PubMed Web of Science ®Google Scholar
• Chang, C. P., Y. Jacobs, T. Nakamura, N. A. Jenkins, N. G. Copeland, and M. L. Cleary. 1997. MEIS proteins are major in vivo DNA binding partners for wild-type but not chimeric Pbx proteins. Mol. Cell. Biol. 17: 5679–5687.
   PubMed Web of Science ®Google Scholar
• Chao, S. H., K. Fujinaga, J. E. Marion, R. Taube, E. A. Sausville, A. M. Senderowicz, B. M. Peterlin, and D. H. Price. 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275: 28345–28348.
   PubMed Web of Science ®Google Scholar
• Chao, S. H., and D. H. Price. 2001. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276: 31793–31799.
   PubMed Web of Science ®Google Scholar
• Clay, F. J., S. J. McEwen, I. Bertoncello, A. F. Wilks, and A. R. Dunn. 1993. Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. Proc. Natl. Acad. Sci. USA 90: 4882–4886.
   PubMed Web of Science ®Google Scholar
• Cupelli, L., S. A. Okenquist, A. Trubetskoy, and J. Lenz. 1998. The secondary structure of the R region of a murine leukemia virus is important for stimulation of long terminal repeat-driven gene expression. J. Virol. 72: 7807–7814.
   PubMed Web of Science ®Google Scholar
• Cupelli, L. A., and J. Lenz. 1991. Transcriptional initiation and postinitiation effects of murine leukemia virus long terminal repeat R-region sequences. J. Virol. 65: 6961–6968.
   PubMed Web of Science ®Google Scholar
• DesGroseillers, L., and P. Jolicoeur. 1984. The tandem direct repeats within the long terminal repeat of murine leukemia viruses are the primary determinant of their leukemogenic potential. J. Virol. 52: 945–952.
   PubMed Web of Science ®Google Scholar
• DiFronzo, N. L., and C. A. Holland. 1999. Sequence-specific and/or stereospecific constraints of the U3 enhancer elements of MCF 247-W are important for pathogenicity. J. Virol. 73: 234–241.
   PubMedGoogle Scholar
• Dyson, N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev. 12: 2245–2262.
   PubMed Web of Science ®Google Scholar
• Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494–498.
   PubMed Web of Science ®Google Scholar
• Golemis, E. A., N. A. Speck, and N. Hopkins. 1990. Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design. J. Virol. 64: 534–542.
   PubMedGoogle Scholar
• Gray, N., L. Detivaud, C. Doerig, and L. Meijer. 1999. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6: 859–875.
   PubMed Web of Science ®Google Scholar
• Gray, N. S. 1995. Synthesis and biological application of 2,6,9-trisubstituted purine libraries. Ph.D. thesis. University of California, Berkeley.
   Google Scholar
• Gray, N. S., L. Wodicka, A. M. Thunnissen, T. C. Norman, S. Kwon, F. H. Espinoza, D. O. Morgan, G. Barnes, S. Leclerc, L. Meijer, S. H. Kim, D. J. Lockhart, and P. G. Schultz. 1998. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533–538.
   PubMed Web of Science ®Google Scholar
• Gunzburg, W. H., A. Fleuchaus, R. Saller, and B. Salmons. 1996. Retroviral vector targeting for gene therapy. Cytokines Mol. Ther. 2: 177–184.
   PubMedGoogle Scholar
• Hajduch, M., L. Havlieek, J. Vesely, R. Novotny, V. Mihal, and M. Strnad. 1999. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv. Exp. Med. Biol. 457: 341–353.
   PubMedGoogle Scholar
• Hatakeyama, M., and R. A. Weinberg. 1995. The role of RB in cell cycle control. Prog. Cell Cycle Res. 1: 9–19.
   PubMedGoogle Scholar
• Henderson, A., M. Bunce, N. Siddon, R. Reeves, and D. J. Tremethick. 2000. High-mobility-group protein I can modulate binding of transcription factors to the U5 region of the human immunodeficiency virus type 1 proviral promoter. J. Virol. 74: 10523–10534.
   PubMedGoogle Scholar
• Kagawa, N., A. Ogo, Y. Takahashi, A. Iwamatsu, and M. R. Waterman. 1994. A cAMP-regulatory sequence (CRS1) of CYP17 is a cellular target for the homeodomain protein PBX1. J. Biol. Chem. 269: 18716–18719.
   PubMed Web of Science ®Google Scholar
• Knoepfler, P. S., K. R. Calvo, H. Chen, S. E. Antonarakis, and M. P. Kamps. 1997. MEIS1 and pKnox1 bind DNA cooperatively with PBX1 utilizing an interaction surface disrupted in oncoprotein E2a-PBX1. Proc. Natl. Acad. Sci. USA 94: 14553–14558.
   PubMed Web of Science ®Google Scholar
• Knoepfler, P. S., and M. P. Kamps. 1997. The highest affinity DNA element bound by Pbx complexes in t(1;19) leukemic cells fails to mediate cooperative DNA-binding or cooperative transactivation by E2a-PBX1 and class I Hox proteins—evidence for selective targetting of E2a-PBX1 to a subset of Pbx-recognition elements. Oncogene 14: 2521–2531.
   PubMedGoogle Scholar
• Lam, L. T., O. K. Pickeral, A. C. Peng, A. Rosenwald, E. M. Hurt, J. M. Giltnane, L. M. Averett, H. Zhao, R. E. Davis, M. Sathyamoorthy, L. M. Wahl, E. D. Harris, J. A. Mikovits, A. P. Monks, M. G. Hollingshead, E. A. Sausville, and L. M. Staudt. 2001. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2: research0041.1-0041.11. [Online.] http://genomebiology.com/2001/2/10/research/0041 .
   PubMed Web of Science ®Google Scholar
• Lenz, J., D. Celander, R. L. Crowther, R. Patarca, D. W. Perkins, and W. A. Haseltine. 1984. Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature 308: 467–470.
   PubMed Web of Science ®Google Scholar
• Li, L., K. Yoder, M. S. Hansen, J. Olvera, M. D. Miller, and F. D. Bushman. 2000. Retroviral cDNA integration: stimulation by HMG I family proteins. J. Virol. 74: 10965–10974.
   PubMedGoogle Scholar
• Li, Y., E. Golemis, J. W. Hartley, and N. Hopkins. 1987. Disease specificity of nondefective Friend and Moloney murine leukemia viruses is controlled by a small number of nucleotides. J. Virol. 61: 693–700.
   PubMedGoogle Scholar
• Lobel, L. I., and S. P. Goff. 1985. Reverse transcription of retroviral genomes: mutations in the terminal repeat sequences. J. Virol. 53: 447–455.
   PubMed Web of Science ®Google Scholar
• Lockhart, D. J., H. Dong, M. C. Byrne, M. T. Follettie, M. V. Gallo, M. S. Chee, M. Mittmann, C. Wang, M. Kobayashi, H. Horton, and E. L. Brown. 1996. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 14: 1675–1680.
   PubMed Web of Science ®Google Scholar
• Mancebo, H. S., G. Lee, J. Flygare, J. Tomassini, P. Luu, Y. Zhu, J. Peng, C. Blau, D. Hazuda, D. Price, and O. Flores. 1997. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 11: 2633–2644.
   PubMed Web of Science ®Google Scholar
• Morgan, D. O. 1997. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13: 261–291.
   PubMed Web of Science ®Google Scholar
• Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18: 3587–3596.
   PubMed Web of Science ®Google Scholar
• Murphy, J. E., and S. P. Goff. 1989. Construction and analysis of deletion mutations in the U5 region of Moloney murine leukemia virus: effects on RNA packaging and reverse transcription. J. Virol. 63: 319–327.
   PubMedGoogle Scholar
• Nikolaychik, V. V., M. M. Samet, and P. I. Lelkes. 1996. A new method for continual quantitation of viable cells on endothelialized polyurethanes. J. Biomater. Sci. Polym. Ed. 7: 881–891.
   PubMed Web of Science ®Google Scholar
• Northrop, J. P., S. N. Ho, L. Chen, D. J. Thomas, L. A. Timmerman, G. P. Nolan, A. Admon, and G. R. Crabtree. 1994. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 369: 497–502.
   PubMed Web of Science ®Google Scholar
• Nuell, M. J., D. A. Stewart, L. Walker, V. Friedman, C. M. Wood, G. A. Owens, J. R. Smith, E. L. Schneider, R. Dell'Orco, C. K. Lumpkin, D. B. Danner, and J. K. McClung. 1991. Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells. Mol. Cell. Biol. 11: 1372–1381.
   PubMed Web of Science ®Google Scholar
• Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90: 8392–8396.
   PubMed Web of Science ®Google Scholar
• Portis, J. L., S. Perryman, and F. J. McAtee. 1991. The R-U5-5′ leader sequence of neurovirulent wild mouse retrovirus contains an element controlling the incubation period of neurodegenerative disease. J. Virol. 65: 1877–1883.
   PubMedGoogle Scholar
• Price, D. H. 2000. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol. 20: 2629–2634.
   PubMed Web of Science ®Google Scholar
• Roe, T., T. C. Reynolds, G. Yu, and P. O. Brown. 1993. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12: 2099–2108.
   PubMed Web of Science ®Google Scholar
• Sasaki, K., H. Shima, Y. Kitagawa, S. Irino, T. Sugimura, and M. Nagao. 1990. Identification of members of the protein phosphatase 1 gene family in the rat and enhanced expression of protein phosphatase 1 alpha gene in rat hepatocellular carcinomas. Jpn. J. Cancer Res. 81: 1272–1280.
   PubMedGoogle Scholar
• Sausville, E. A., J. Johnson, M. Alley, D. Zaharevitz, and A. M. Senderowicz. 2000. Inhibition of CDKs as a therapeutic modality. Ann. N. Y. Acad. Sci. 910: 207–221.
   PubMed Web of Science ®Google Scholar
• Schang, L. M., J. Phillips, and P. A. Schaffer. 1998. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 72: 5626–5637.
   PubMed Web of Science ®Google Scholar
• Schang, L. M., A. Rosenberg, and P. A. Schaffer. 1999. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J. Virol. 73: 2161–2172.
   PubMed Web of Science ®Google Scholar
• Selleri, L., M. J. Depew, Y. Jacobs, S. K. Chanda, K. Y. Tsang, K. S. Cheah, J. L. Rubenstein, S. O'Gorman, and M. L. Cleary. 2001. Requirement for PBX1 in skeletal patterning and programming chondrocyte proliferation and differentiation. Development 128: 3543–3557.
   PubMedGoogle Scholar
• Senderowicz, A. M. 1999. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investig. New Drugs 17: 313–320.
   PubMed Web of Science ®Google Scholar
• Senderowicz, A. M., and E. A. Sausville. 2000. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 92: 376–387.
   PubMed Web of Science ®Google Scholar
• Shanmugam, K., N. C. Green, I. Rambaldi, H. U. Saragovi, and M. S. Featherstone. 1999. PBX and MEIS as non-DNA-binding partners in trimeric complexes with HOX proteins. Mol. Cell. Biol. 19: 7577–7588.
   PubMed Web of Science ®Google Scholar
• Shen, W. F., S. Rozenfeld, A. Kwong, L. G. Kümüves, H. J. Lawrence, and C. Largman. 1999. HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Mol. Cell. Biol. 19: 3051–3061.
   PubMed Web of Science ®Google Scholar
• Sourvinos, G., C. Tsatsanis, and D. A. Spandidos. 2000. Mechanisms of retrovirus-induced oncogenesis. Folia Biol. (Prague) 46: 226–232.
   PubMedGoogle Scholar
• Wang, D., C. de la Fuente, L. Deng, L. Wang, I. Zilberman, C. Eadie, M. Healey, D. Stein, T. Denny, L. E. Harrison, L. Meijer, and F. Kashanchi. 2001. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75: 7266–7279.
   PubMed Web of Science ®Google Scholar
• Zhu, Y., T. Pe'ery, J. Peng, Y. Ramanathan, N. Marshall, T. Marshall, B. Amendt, M. B. Mathews, and D. H. Price. 1997. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11: 2622–2632.
   PubMed Web of Science ®Google Scholar